Beth israel medical center
Brigham and womens hospital
Dana farber cancer institute
Hackensack university medical center
Jacobi medical center
Lenox hill hospital
Montefiore medical center
New york and presbyterian hospital
New york methodist hospital
North shore university hospital
Memorial Hospital For Cancer and Allied Diseases
Inclusion of patients with brain metastases in phase I trials: an unmet need.
Clin. Cancer Res., Jun;17(12):3855-7 (2011)
Dual-fluorescence isogenic high-content screening for MUC16/CA125 selective agents.
Mol. Cancer Ther., Oct;10(10):1939-48 (2011)
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
J. Clin. Oncol., Dec;29(35):4662-8 (2011)
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Mod. Pathol., Apr;25(4):625-36 (2012)
New drugs for ovarian cancer.
Ann. Oncol., Dec;22 Suppl 8:viii77-viii82 (2011)
Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
Gynecol. Oncol., Aug;126(2):224-8 (2012)
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
Int. J. Gynecol. Cancer., 17(1):197-203 (2007)
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Clin. Cancer Res., Jul;13(14):4170-7 (2007)
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
J. Clin. Oncol., Oct;25(28):4466-71 (2007)
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
Clin. Cancer Res., May;14(9):2740-8 (2008)
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Gynecol. Oncol., Aug;110(2):140-5 (2008)
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
Clin Trials., 5(5):465-77 (2008)
The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.
Gynecol. Oncol., Mar;116(3):326-31 (2010)
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
Clin. Cancer Res., Jan;16(1):358-66 (2010)
Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.
Appl. Immunohistochem. Mol. Morphol., Oct;18(5):462-72 (2010)
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
Clin. Cancer Res., Jul;16(14):3594-606 (2010)
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
J. Clin. Oncol., Jun;20(12):2824-31 (2002)
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
Clin. Cancer Res., Aug;8(8):2505-11 (2002)